AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 154 min read$MACBearishMed

Macerich Announces Commencement of Public Offering of Common Stock

Macerich (NYSE: MAC) said it has started an underwritten public offering of 14,000,000 shares of common stock, with Goldman Sachs & Co. LLC as lead bookrunner. The underwriters have a 30-day option to buy up to 2,100,000 additional shares. Macerich expects to enter forward sale agreements with financial institutions; it will not receive initial proceeds, with net proceeds expected upon future settlement to fund acquisitions and general corporate purposes.

AI DeskJune 15, 2026
Source · manilatimes.net
AI analysis
Relevance
7/10
Novelty
8/10
Actionability
Med
Sentiment · $MAC
Bearish
Timing
offering commenced June 15, 2026; forward settlement dates extend to no later than June 16, 2027
Market alignment
likely risk-off for MAC equity due to dilution/financing optics, partially offset by stated acquisition funding intent
Why this matters for $MAC

Dilutive equity issuance mechanics (forward sale + potential option) can pressure MAC’s near-term valuation, while proceeds are earmarked for acquisitions/general corporate use.

Relevance context

Macerich commenced an underwritten public offering of 14,000,000 shares via forward sale agreements, with an option for 2,100,000 more.

Price-impact prediction

Choppy-to-negative bias around the offering execution and any subsequent pricing/settlement details; longer-dated impact depends on acquisition deployment.

Background

Macerich (a self-managed REIT) announced commencement of an underwritten public offering using forward sale agreements, with underwriters able to buy an additional tranche via a 30-day option.

Why it matters

The offering is designed to set the share price at offering pricing while delaying issuance/cash receipt until future settlement; net proceeds (if any) are intended for acquisitions and general corporate purposes.

Market relevance

Traders should focus on dilution expectations, offering pricing/terms (not provided here), and the timeline for settlement and capital deployment.

Market effects

Sector

Adds to the broader REIT financing/issuance narrative; may modestly influence sentiment toward retail REIT peers if capital markets are tight.

Regional

No direct regional read-through beyond general US retail real estate capital availability.

Global

Primarily US capital markets/REIT-specific; limited global spillover.

Alternative perspectives

Contrarian view

Forward sale structure delays cash receipt and can help manage timing; if acquisition pipeline is strong, the market may re-rate MAC after settlement/pricing clarity.

Overlooked factors

Key sensitivities are the forward sale price terms, any hedging/net share settlement election conditions, and how quickly management deploys capital into accretive acquisitions.

Key entities

  • company
    Macerich

    Announced commencement of an underwritten public offering of common stock via forward sale agreements.

  • financial_institution
    Goldman Sachs & Co. LLC

    Lead bookrunner/representative of underwriters for the offering.

Read at source← All news

Related articles

JUN 17
$MACMed

Macerich (NYSE:MAC) Stock Rating Upgraded by JPMorgan Chase & Co.

JPMorgan upgraded Macerich (NYSE:MAC) from “underweight” to “neutral” and set a $25.00 price target, implying 5.34% upside from the prior close, according to MarketBeat. Other firms cited include Deutsche Bank (to “buy,” $27 target) and Goldman Sachs (to “sell,” $19 target). Macerich reported $0.34 EPS and $241.54M revenue for Q ended May 6.

dailypolitical.com4 min
JUL 13
$DECKMed

Jefferies bullish on Deckers Outdoor, sees HOKA growth slowdown as oversold By Investing.com

Jefferies upgraded Deckers Outdoor (DECK) to Buy from Hold, saying the stock has been overly penalized for a HOKA growth slowdown that appears reflected in the price. The firm cites Deckers medium-term guidance: high-single-digit revenue growth, low-20% operating margins, and low-double-digit EPS growth with buybacks. It expects HOKA improvement tied to product innovation and segmentation, noting cash at 13% of market cap.

investing.com3 min
JUL 13
$ATLXMed

Atlas Lithium Receives Strong Product Demand; On Track for Commercial Production in 2027

Atlas Lithium (NASDAQ: ATLX) said its 100%-owned Neves Project is on track for first commercial production of lithium oxide concentrate in Q4 2027. The company plans about 150,000 tonnes per year and reported written product interest totaling over 3x capacity. It cited DFS economics of 145% after-tax IRR, 11-month payback, and $489 per tonne operating costs.

thailand-business-news.com3 min
JUL 13
$ATLXMed

Atlas Lithium (NASDAQ: ATLX) said its 100% owned Neves Project in Brazil is on track for first commercial production of lithium oxide concentrate in Q4 2027

Atlas Lithium (NASDAQ: ATLX) said its 100% owned Neves Project in Brazil is on track for first commercial production of lithium oxide concentrate in Q4 2027. The company targets about 150,000 tonnes per year and reports written product interest totaling over three times capacity. It cites DFS economics of 145% after-tax IRR and 11-month payback, with operating costs of $489 per tonne.

acnnewswire.com3 min
JUL 13
$AXPMed

American Express, Biogen upgraded: Wall Street's top analyst calls

Wall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).

yahoo.com4 min